These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26757360)

  • 1. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.
    Barat S; Bozko P; Chen X; Scholta T; Hanert F; Götze J; Malek NP; Wilkens L; Plentz RR
    Mol Carcinog; 2016 Dec; 55(12):2037-2050. PubMed ID: 26757360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
    Wei K; Li M; Zöller M; Wang M; Mehrabi A; Hoffmann K
    Cell Death Dis; 2019 Mar; 10(3):231. PubMed ID: 30850583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
    Wu W; Bi C; Credille KM; Manro JR; Peek VL; Donoho GP; Yan L; Wijsman JA; Yan SB; Walgren RA
    Clin Cancer Res; 2013 Oct; 19(20):5699-710. PubMed ID: 23989980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
    Yan SB; Peek VL; Ajamie R; Buchanan SG; Graff JR; Heidler SA; Hui YH; Huss KL; Konicek BW; Manro JR; Shih C; Stewart JA; Stewart TR; Stout SL; Uhlik MT; Um SL; Wang Y; Wu W; Yan L; Yang WJ; Zhong B; Walgren RA
    Invest New Drugs; 2013 Aug; 31(4):833-44. PubMed ID: 23275061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Met targeted therapy of cholangiocarcinoma.
    Socoteanu MP; Mott F; Alpini G; Frankel AE
    World J Gastroenterol; 2008 May; 14(19):2990-4. PubMed ID: 18494048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
    Kawada I; Hasina R; Arif Q; Mueller J; Smithberger E; Husain AN; Vokes EE; Salgia R
    Cancer Res; 2014 Feb; 74(3):884-95. PubMed ID: 24305878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma.
    El Khatib M; Kalnytska A; Palagani V; Kossatz U; Manns MP; Malek NP; Wilkens L; Plentz RR
    Hepatology; 2013 Mar; 57(3):1035-45. PubMed ID: 23172661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
    Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
    Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
    Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
    BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
    Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal‑regulated kinase signaling pathway.
    Vanichapol T; Leelawat K; Hongeng S
    Mol Med Rep; 2015 Sep; 12(3):3265-3272. PubMed ID: 26018028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Inhibition of Sonic Hedgehog Signaling Suppresses Tumor Development in a Murine Model of Intrahepatic Cholangiocarcinoma.
    Cho K; Moon H; Seo SH; Ro SW; Kim BK
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells.
    Ge X; Wang Y; Wang Y; Li Q; Yu H; Miao L
    Dig Dis Sci; 2013 Jun; 58(6):1636-43. PubMed ID: 23314853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL Enhances Shikonin Induced Apoptosis through ROS/JNK Signaling in Cholangiocarcinoma Cells.
    Zhou G; Yang Z; Wang X; Tao R; Zhou Y
    Cell Physiol Biochem; 2017; 42(3):1073-1086. PubMed ID: 28662515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met.
    Leelawat K; Leelawat S; Tepaksorn P; Rattanasinganchan P; Leungchaweng A; Tohtong R; Sobhon P
    J Surg Res; 2006 Nov; 136(1):78-84. PubMed ID: 16950403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.